[Skip to Content]
[Skip to Content Landing]
Citations 0
July 15, 2009

Carotid Atherosclerosis Progression and ACAT Inhibition

JAMA. 2009;302(3):255-257. doi:10.1001/jama.2009.1000

To the Editor: Dr Meuwese and colleagues1 presented results of the Carotid Atherosclerosis Progression Trial Investigating Vascular ACAT Inhibition Treatment Effects (CAPTIVATE). In this study, patients who were heterozygous for familial hypercholesterolemia were randomized to receive either pactimibe (a nonspecific acyl coenzyme A:cholesterol acyltransferase [ACAT] inhibitor) or placebo, in addition to standard lipid-lowering therapy. Consistent with data from macrophage ACAT1 knockout mice, treatment with a nonspecific ACAT inhibitor may not result in apparent positive effects on atherosclerosis.2

First Page Preview View Large
First page PDF preview
First page PDF preview